Breaking News
December 15, 2017 - Outcomes Poorer for Black Patients with Early Breast Ca
December 15, 2017 - Liposuction May Ease Limb Swelling in Cancer Patients
December 15, 2017 - How well can digital assistants answer questions on sex?
December 15, 2017 - NIH-funded study to explore hearing loss risk in Detroit firefighters
December 15, 2017 - Caris Life Sciences reveals identification of new mechanism of action to treat NHL
December 15, 2017 - Loyola Medicine study finds high success rate for diabetic Charcot foot surgery
December 15, 2017 - Bone marrow edema does not increase due to intense physical activity, study finds
December 15, 2017 - Human ‘common cold’ virus kills healthy chimpanzees in Uganda
December 15, 2017 - Experience of reflex walking refines perception of biological motion during early infancy
December 15, 2017 - FDA Approves Admelog (insulin lispro) Rapid-Acting “Follow-On” Insulin Product to Treat Diabetes
December 14, 2017 - Friday Feedback: Good Idea for Ex-Pharma Exec to Run HHS?
December 14, 2017 - More than 200 people sickened onboard Ovation of Seas cruise
December 14, 2017 - FDA announces new approach for sharing updates on antibiotics, antifungal drugs to physicians
December 14, 2017 - Steroid study provides new insights into medicines’ side effects
December 14, 2017 - Government announces plans to include eye test reminder during driving license renewal
December 14, 2017 - Non-ionizing radiation from magnetic fields could have adverse biological impacts on health
December 14, 2017 - Bi-annual MRI beats mammograms in detecting breast cancer among women with genetic risk
December 14, 2017 - Researchers develop new method for quickly detecting signs of multiple sclerosis
December 14, 2017 - In era of increased competition, hospitals fret over ratings
December 14, 2017 - Female veterans experience improvement in low back pain with course of chiropractic care
December 14, 2017 - Relieving Symptoms of Cystic Fibrosis with Exercise
December 14, 2017 - FDA Alert: Blue Pearl All Natural Male Enhancement Supplement: Recall
December 14, 2017 - CardioBrief: In Defense Of ORBITA
December 14, 2017 - Definition of High Blood Pressure Drops: MedlinePlus Health News
December 14, 2017 - Drug may help surgical patients stop opioids sooner
December 14, 2017 - Researchers develop biosensor that enables development of new health tests
December 14, 2017 - Radiation therapy can be used to treat patients with life-threatening heart rhythm
December 14, 2017 - UVA researchers developing tool to help prostate cancer patients weigh treatment options
December 14, 2017 - Experts tell Congress how to cut drug prices
December 14, 2017 - Researchers use cryptographic techniques to decode activity of motor neurons
December 14, 2017 - Study finds changes in the heart after spinal cord injury
December 14, 2017 - Health Highlights: Dec. 12, 2017
December 14, 2017 - Pelzman’s Picks: How States Can Cut Disparities in Care and Costs
December 14, 2017 - New Hemophilia Treatment Stems Bleeding Episodes: MedlinePlus Health News
December 14, 2017 - Onetime ‘world’s heaviest man’ has second surgery in Mexico
December 14, 2017 - Belgian researchers create transplantable artificial ovary prototype
December 14, 2017 - Using atraumatic needles for lumbar punctures decreases risk of complications
December 14, 2017 - Outpatient total knee replacement surgery linked to higher rates of complications
December 14, 2017 - Social impairments can be corrected by brain stimulation
December 14, 2017 - Studies reveal possibility for memory T cells to serve a dual purpose
December 14, 2017 - Antibody-Drug Conjugate Ups PFS in Untreated Hodgkin’s
December 14, 2017 - Study finds reading information aloud to yourself improves memory
December 14, 2017 - Researchers use RNA nanotechnology to program exosomes for delivering effective cancer therapies
December 14, 2017 - Living Lyme disease bacteria found months after antibiotic treatment
December 14, 2017 - These annual checkups help seniors not only survive but thrive
December 14, 2017 - Study reveals impact of diabetes during pregnancy on baby’s heart
December 14, 2017 - Hydraulic fracturing is harmful to infants health, study states
December 14, 2017 - Huntington’s disease drug clears initial hurdles
December 14, 2017 - TPU researchers create 3D-printed models of children’s hearts
December 14, 2017 - Brain responses of children with inherited dyslexia risk predict their future reading speed
December 14, 2017 - People diagnosed with schizophrenia or bipolar disorder may actually have treatable condition
December 14, 2017 - Study: New Furosemide Formulation Simplifies Administration for HF
December 14, 2017 - Discrimination harms your health—and your partner’s
December 14, 2017 - Having older brothers may increase the likelihood of being gay
December 14, 2017 - New scientific yardstick released to help early detection of Alzheimer’s disease
December 14, 2017 - New finding demonstrates what happens at cellular level during onset of type2 diabetes
December 14, 2017 - Study identifies potassium as key to circadian rhythms in red blood cells
December 14, 2017 - Good friends might be your best brain booster as you age
December 14, 2017 - NIH expected to award up to $70 million to launch Alzheimer’s Clinical Trials Consortium
December 14, 2017 - Pitting pathogens against each other could prevent drug resistance emerging
December 14, 2017 - Study provides new insights into development of Sonic Hedgehog medulloblastoma
December 14, 2017 - Dr. Reddy’s Announces Approval of Impoyz (clobetasol propionate) Cream for Plaque Psoriasis
December 14, 2017 - Gene Screens Can Alter Perception, Behavior
December 14, 2017 - Can Scrotal Vein Condition Hike Heart Risks?: MedlinePlus Health News
December 14, 2017 - Molecules in spit may be able to diagnose and predict length of concussions
December 14, 2017 - Children’s Colorado and RxRevu partner to help prescribers better meet needs of pediatric patients
December 14, 2017 - Researchers discover new way to attack drug-resistant prostate cancer cells
December 14, 2017 - Scientists develop new, high resolution method for identifying microbial species and strains
December 14, 2017 - Declining trend of salmonellosis cases has leveled off in the EU
December 14, 2017 - Death receptors in the blood can help measure risk of cardiovascular diseases, type 2 diabetes
December 14, 2017 - How to Perk Up the Holidays for Hospital Patients
December 14, 2017 - Prolonged Sedation May be Bad for Baby’s Brain
December 14, 2017 - The pediatric submersion score predicts children at low risk for injury following submersions
December 14, 2017 - Video game helps doctors to quickly recognize trauma patients who need high levels of care
December 14, 2017 - Younger persons newly-diagnosed with type 2 diabetes have poorer health than older patients
December 14, 2017 - Clinician re-examines evidence on re-use of catheters and UTIs in people with spinal cord injuries
December 14, 2017 - UK and Russian researchers join forces against AMR
December 14, 2017 - Results of Bariatric Surgery Hold Up Over Time
December 14, 2017 - High-intensity exercise delays Parkinson’s progression
December 14, 2017 - Protein structure could pave way for effective drugs to treat cystic fibrosis
FDA Approves Mepsevii (vestronidase alfa) for Mucopolysaccharidosis Type VII

FDA Approves Mepsevii (vestronidase alfa) for Mucopolysaccharidosis Type VII

image_pdfDownload PDFimage_print

FDA Approves Mepsevii (vestronidase alfa) for Mucopolysaccharidosis Type VII

November 15, 2017 — The U.S. Food and Drug Administration today approved Mepsevii (vestronidase alfa-vjbk) to treat pediatric and adult patients with an inherited metabolic condition called mucopolysaccharidosis type VII (MPS VII), also known as Sly syndrome. MPS VII is an extremely rare, progressive condition that affects most tissues and organs.
“This approval underscores the agency’s commitment to making treatments available to patients with rare diseases,” said Julie Beitz, M.D., director of the Office of Drug Evaluation III in the FDA’s Center for Drug Evaluation and Research (CDER). “Prior to today’s approval, patients with this rare, inherited condition had no approved treatment options.”

MPS VII is an inherited, rare genetic condition and impacts less than 150 patients worldwide. The features of MPS VII vary widely from patient to patient, but most patients have various skeletal abnormalities that become more pronounced with age, including short stature. Affected individuals can also develop heart valve abnormalities, enlarged liver and spleen, and narrowed airways which can lead to lung infections and trouble breathing. The life expectancy of individuals with MPS VII depends on the severity of symptoms. Some affected individuals do not survive infancy, while others may live into adolescence or adulthood. Heart disease and airway obstruction are major causes of death in people with MPS VII. Affected individuals may have developmental delay and progressive intellectual disability.

The safety and efficacy of Mepsevii were established in clinical trial and expanded access protocols enrolling a total of 23 patients ranging from 5 months to 25 years of age. Patients received treatment with Mepsevii at doses up to 4 mg/kg once every two weeks for up to 164 weeks. Efficacy was primarily assessed via the six-minute walk test in ten patients who could perform the test. After 24 weeks of treatment, the mean difference in distance walked relative to placebo was 18 meters. Additional follow-up for up to 120 weeks suggested continued improvement in three patients and stabilization in the others. Two patients in the Mepsevii development program experienced marked improvement in pulmonary function. Overall, the results observed would not have been anticipated in the absence of treatment. The effect of Mepsevii on the central nervous system manifestations of MPS VII has not been determined.

The most common side effects after treatment with Mepsevii include infusion site reactions, diarrhea, rash and anaphylaxis.

The FDA granted this application Fast Track designation, which seeks to expedite the development and review of drugs that are intended to treat serious conditions where initial evidence showed the potential to address an unmet medical need. Mepsevii also received Orphan Drug designation, which provides incentives to assist and encourage the development of drugs for rare diseases.

The sponsor is receiving a Rare Pediatric Disease Priority Review Voucher under a program intended to encourage development of new drugs and biologics for the prevention and treatment of rare pediatric diseases. A voucher can be redeemed by a sponsor at a later date to receive Priority Review of a subsequent marketing application for a different product. This is the twelfth rare pediatric disease priority review voucher issued by the FDA since the program began.

The FDA is requiring the manufacturer to conduct a post-marketing study to evaluate the long-term safety of the product.

The FDA granted approval of Mepsevii to Ultragenyx Pharmaceutical, Inc.

Source: FDA

Posted: November 2017

Mepsevii (vestronidase alfa) FDA Approval History

Tagged with:

About author

Related Articles